{"id":"azithromycin-and-rifampin","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal pain)"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Drug interactions"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Azithromycin is a macrolide antibiotic that binds to the bacterial 50S ribosomal subunit and inhibits protein synthesis. Rifampin is a rifamycin that inhibits bacterial RNA polymerase, blocking transcription. Together, they provide broad-spectrum antimicrobial coverage with potential synergistic activity against certain pathogens, particularly mycobacteria and intracellular organisms.","oneSentence":"Azithromycin and rifampin are a combination of two antibiotics that work synergistically to inhibit bacterial protein synthesis and RNA polymerase, respectively, to treat infections.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:43:10.185Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mycobacterial infections (likely tuberculosis or nontuberculous mycobacteria)"},{"name":"Respiratory tract infections with intracellular pathogens"}]},"trialDetails":[{"nctId":"NCT05994742","phase":"PHASE3","title":"An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Queen Mary University of London","startDate":"2024-07-15","conditions":"Severe Acute Malnutrition, HIV, Comorbidities and Coexisting Conditions","enrollment":674},{"nctId":"NCT05894954","phase":"PHASE3","title":"Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Alzheimer's Prevention and Reversal Project, Inc.","startDate":"2023-07-31","conditions":"Mild Cognitive Impairment, Dementia, Mild","enrollment":73},{"nctId":"NCT03672630","phase":"PHASE2, PHASE3","title":"Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease","status":"COMPLETED","sponsor":"Kevin Winthrop","startDate":"2019-02-22","conditions":"Mycobacterium Avium Complex, Nontuberculous Mycobacterium Infection","enrollment":474},{"nctId":"NCT03236987","phase":"PHASE3","title":"CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2018-02-05","conditions":"Lung Infection, MAC Lung Disease","enrollment":424},{"nctId":"NCT07084402","phase":"PHASE4","title":"Short-term Bactericidal Effect of Contezolid in MAC-PD","status":"RECRUITING","sponsor":"Bin Cao","startDate":"2025-07-24","conditions":"Mycobacterium Avium Complex Pulmonary Disease","enrollment":188},{"nctId":"NCT00127504","phase":"PHASE2","title":"Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2003-07","conditions":"Onchocerciasis","enrollment":80},{"nctId":"NCT03237182","phase":"PHASE4","title":"The Individualized M(X) Drug-resistant TB Treatment Strategy Study","status":"TERMINATED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2017-06-14","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":205},{"nctId":"NCT04553406","phase":"PHASE2","title":"Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease","status":"TERMINATED","sponsor":"Spero Therapeutics","startDate":"2020-12-03","conditions":"Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease","enrollment":2},{"nctId":"NCT00000641","phase":"PHASE2","title":"A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Mycobacterium Avium-intracellulare Infection, HIV Infections","enrollment":90},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT02372383","phase":"NA","title":"Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2014-10","conditions":"Cystic Fibrosis","enrollment":31},{"nctId":"NCT02024555","phase":"PHASE2","title":"Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2014-03","conditions":"Sarcoidosis; Antimycobacterial Therapy","enrollment":97},{"nctId":"NCT00351273","phase":"PHASE3","title":"Combination Antibiotic Treatment for Reactive Arthritis Caused by Chlamydia Bacteria","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2006-05","conditions":"Arthritis, Reactive, Reiter Disease","enrollment":42},{"nctId":"NCT00598962","phase":"PHASE4","title":"Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at Tyler","startDate":"1994-12","conditions":"Mycobacterium Avium Complex","enrollment":58},{"nctId":"NCT01074554","phase":"PHASE1, PHASE2","title":"Trial of Antimycobacterial Therapy in Sarcoidosis","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2010-02","conditions":"Sarcoidosis","enrollment":30},{"nctId":"NCT01169038","phase":"PHASE1","title":"Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2010-07","conditions":"Pulmonary Sarcoidosis, Lung Function","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zithromax and Rifadin"],"phase":"phase_3","status":"active","brandName":"Azithromycin and Rifampin","genericName":"Azithromycin and Rifampin","companyName":"University of South Florida","companyId":"university-of-south-florida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Azithromycin and rifampin are a combination of two antibiotics that work synergistically to inhibit bacterial protein synthesis and RNA polymerase, respectively, to treat infections. Used for Mycobacterial infections (likely tuberculosis or nontuberculous mycobacteria), Respiratory tract infections with intracellular pathogens.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}